Proliferating cell nuclear antigen

Function

The protein encoded by this gene is found in the nucleus and is a cofactor of DNA polymerase delta. The encoded protein acts as a homotrimer and helps increase the processivity of leading strand synthesis during DNA replication. In response to DNA damage, this protein is ubiquitinated and is involved in the RAD6-dependent DNA repair pathway. Two transcript variants encoding the same protein have been found for this gene. Pseudogenes of this gene have been described on chromosome 4 and on the X chromosome.

PCNA is also ubiquitous in archaea, where it typically serves as a processivity factor for the replicative polymerases, particularly for polD. However, in the Sulfolobus genus, it also functions as a processivity factor for the replicative polB polymerase.

Expression in the nucleus during DNA synthesis

PCNA was originally identified as an antigen that is expressed in the nuclei of cells during the DNA synthesis phase of the cell cycle. Part of the protein was sequenced and that sequence was used to allow isolation of a cDNA clone. PCNA helps hold DNA polymerase delta (Pol δ) to DNA. PCNA is clamped to DNA through the action of replication factor C (RFC), which is a heteropentameric member of the AAA+ class of ATPases. Expression of PCNA is under the control of E2F transcription factor-containing complexes.

Role in DNA repair

Since DNA polymerase epsilon is involved in resynthesis of excised damaged DNA strands during DNA repair, PCNA is important for both DNA synthesis and DNA repair.

PCNA is also involved in the DNA damage tolerance pathway known as post-replication repair (PRR). In PRR, there are two sub-pathways: (1) a translesion synthesis pathway, which is carried out by specialised DNA polymerases that are able to incorporate damaged DNA bases into their active sites (unlike the normal replicative polymerase, which stall), and hence bypass the damage, and (2) a proposed "template switch" pathway that is thought to involve damage bypass by recruitment of the homologous recombination machinery. PCNA is pivotal to the activation of these pathways and the choice as to which pathway is utilised by the cell. PCNA becomes post-translationally modified by ubiquitin. Mono-ubiquitin of lysine number 164 on PCNA activates the translesion synthesis pathway. Extension of this mono-ubiquitin by a non-canonical lysine-63-linked poly-ubiquitin chain on PCNA is thought to activate the template switch pathway. Furthermore, sumoylation (by small ubiquitin-like modifier, SUMO) of PCNA lysine-164 (and to a lesser extent, lysine-127) inhibits the template switch pathway. This antagonistic effect occurs because sumoylated PCNA recruits a DNA helicase called Srs2, which has a role in disrupting Rad51 nucleoprotein filaments fundamental for initiation of homologous recombination.

PCNA-binding proteins

PCNA interacts with many proteins.

• Apoptotic factors
• ATPases
• Base excision repair enzymes
• Cell-cycle regulators
• Chromatin remodeling factor
• Clamp loader
• Cohesin
• DNA ligase
• DNA methyltransferase
• DNA polymerases
• E2 SUMO-conjugating enzyme
• E3 ubiquitin ligases
• Flap endonuclease
• Helicases
• Histone acetyltransferase
• Histone chaperone
• Histone deacetylase
• Mismatch repair enzymes
• Licensing factor
• NKp44 receptor
• Nucleotide excision repair enzyme
• Poly ADP ribose polymerase
• Procaspases
• Protein kinases
• TCP protein domain
• Topoisomerase

Interactions

PCNA has been shown to interact with:

• Annexin A2
• CAF-1
• CDC25C
• CHTF18
• Cyclin D1
• Cyclin O
• Cyclin-dependent kinase 4
• Cyclin-dependent kinase inhibitor 1C
• DNMT1
• EP300
• Establishment of Sister Chromatid Cohesion 2
• Flap structure-specific endonuclease 1
• GADD45A
• GADD45G
• HDAC1
• HUS1
• ING1
• KCTD13
• KIAA0101
• Ku70
• Ku80
• MCL1
• MSH3
• MSH6
• MUTYH
• P21
• POLD2
• POLD3
• POLDIP2
• POLH
• POLL
• RFC1
• RFC2
• RFC3
• RFC4
• RFC5
• Ubiquitin C
• Werner syndrome ATP-dependent helicase
• XRCC1
• Y box binding protein 1

Proteins interacting with PCNA via APIM include human AlkB homologue 2, TFIIS-L, TFII-I, Rad51B, XPA, ZRANB3, and FBH1.

Uses

Antibodies against proliferating cell nuclear antigen (PCNA) or a similar marker of proliferation termed Ki-67 can be used for grading of different neoplasms, e.g. astrocytoma. They can be of diagnostic and prognostic value. Imaging of the nuclear distribution of PCNA (via antibody labeling) can be used to distinguish between early, mid and late S phase of the cell cycle. However, an important limitation of antibodies is that cells need to be fixed leading to potential artifacts.

On the other hand, the study of the dynamics of replication and repair in living cells can be done by introducing translational fusions of PCNA. To eliminate the need for transfection and bypass the problem of difficult to transfect and/or short lived cells, cell permeable replication and/or repair markers can be used. These peptides offer the distinct advantage that they can be used in situ in living tissue and even distinguish cells undergoing replication from cells undergoing repair.

caPCNA, a post-translationally modified isoform of PCNA common in cancer cells, is a potential therapeutic target in cancer therapy. In 2023 City of Hope National Medical Center published preclinical research on a targeted chemotherapy using AOH1996 that appears to suppress tumor growth without causing discernable side effects.

References

References

1. (March 1998). "PCNA binding through a conserved motif". BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology.
2. (September 2009). "Identification of a novel, widespread, and functionally important PCNA-binding motif". The Journal of Cell Biology.
3. (May 2013). "Regulation of PCNA-protein interactions for genome stability". Nature Reviews. Molecular Cell Biology.
4. "Entrez Gene: PCNA proliferating cell nuclear antigen".
5. (2020-03-27). "Structural basis for the increased processivity of D-family DNA polymerases in complex with PCNA". Nature Communications.
6. (2017-05-02). "Identification and characterization of a heterotrimeric archaeal DNA polymerase holoenzyme". Nature Communications.
7. (May 1992). "PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables". Journal of Clinical Pathology.
8. (March 1987). "Molecular cloning of cDNA coding for rat proliferating cell nuclear antigen (PCNA)/cyclin". The EMBO Journal.
9. (June 2004). "Structural analysis of a eukaryotic sliding DNA clamp-clamp loader complex". Nature.
10. (March 1999). "Studies on the interactions between human replication factor C and human proliferating cell nuclear antigen". Proceedings of the National Academy of Sciences of the United States of America.
11. (December 2002). "Two E2F elements regulate the proliferating cell nuclear antigen promoter differently during leaf development". The Plant Cell.
12. (March 2016). "HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes". Cancer Research.
13. (April 1992). "Proliferating cell nuclear antigen is required for DNA excision repair". Cell.
14. (November 2005). "Nuclear dynamics of PCNA in DNA replication and repair". Molecular and Cellular Biology.
15. (December 2006). "Gaps and forks in DNA replication: Rediscovering old models". DNA Repair.
16. (September 2002). "RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO". Nature.
17. (July 2005). "SUMO-modified PCNA recruits Srs2 to prevent recombination during S phase". Nature.
18. (May 2007). "PCNA, the maestro of the replication fork". Cell.
19. (November 2010). "Proliferating cell nuclear antigen acts as a cytoplasmic platform controlling human neutrophil survival". The Journal of Experimental Medicine.
20. (June 2016). "A DNA binding winged helix domain in CAF-1 functions with PCNA to stabilize CAF-1 at replication forks". Nucleic Acids Research.
21. (February 2000). "A CAF-1-PCNA-mediated chromatin assembly pathway triggered by sensing DNA damage". Molecular and Cellular Biology.
22. (December 2009). "Two fundamentally distinct PCNA interaction peptides contribute to chromatin assembly factor 1 function". Molecular and Cellular Biology.
23. (March 2002). "Cdc25C interacts with PCNA at G2/M transition". Oncogene.
24. (April 1994). "D-type cyclin-binding regions of proliferating cell nuclear antigen". The Journal of Biological Chemistry.
25. (August 1993). "Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation". Genes & Development.
26. (July 1999). "Post-replicative base excision repair in replication foci". The EMBO Journal.
27. (December 1993). "A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4". Nature.
28. (February 1998). "Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen". Proceedings of the National Academy of Sciences of the United States of America.
29. (July 2000). "DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci". Nature Genetics.
30. (October 2002). "PCNA clamp facilitates action of DNA cytosine methyltransferase 1 on hemimethylated DNA". Genes to Cells.
31. (September 1997). "Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1". Science.
32. (March 2001). "Transcription coactivator p300 binds PCNA and may have a role in DNA repair synthesis". Nature.
33. (December 2019). "Multivalent interaction of ESCO2 with replication machinery is required for sister chromatid cohesion in vertebrates". Proceedings of the National Academy of Sciences of the United States of America.
34. (July 2003). "Phosphorylation of human Fen1 by cyclin-dependent kinase modulates its role in replication fork regulation". Oncogene.
35. (June 2001). "Regulation of human flap endonuclease-1 activity by acetylation through the transcriptional coactivator p300". Molecular Cell.
36. (April 1998). "Regulation of DNA replication and repair proteins through interaction with the front side of proliferating cell nuclear antigen". The EMBO Journal.
37. (September 1997). "The DNA repair endonuclease XPG binds to proliferating cell nuclear antigen (PCNA) and shares sequence elements with the PCNA-binding regions of FEN-1 and cyclin-dependent kinase inhibitor p21". Journal of Biological Chemistry.
38. (October 1996). "p21Cip1/Waf1 disrupts the recruitment of human Fen1 by proliferating-cell nuclear antigen into the DNA replication complex". Proceedings of the National Academy of Sciences of the United States of America.
39. (October 2001). "Interaction of human AP endonuclease 1 with flap endonuclease 1 and proliferating cell nuclear antigen involved in long-patch base excision repair". Biochemistry.
40. (January 2001). "p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues". Oncogene.
41. (November 1994). "Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen". Science.
42. (November 1995). "Direct interaction of Gadd45 with PCNA and evidence for competitive interaction of Gadd45 and p21Waf1/Cip1 with PCNA". Oncogene.
43. (June 2000). "Characterization of MyD118, Gadd45, and proliferating cell nuclear antigen (PCNA) interacting domains. PCNA impedes MyD118 AND Gadd45-mediated negative growth control". Journal of Biological Chemistry.
44. (June 1995). "Characterisation of the interaction between PCNA and Gadd45". Oncogene.
45. (November 2000). "Identification of a functional domain in a GADD45-mediated G2/M checkpoint". Journal of Biological Chemistry.
46. (January 2001). "Interaction of CR6 (GADD45gamma ) with proliferating cell nuclear antigen impedes negative growth control". Journal of Biological Chemistry.
47. (August 1999). "A novel oncostatin M-inducible gene OIG37 forms a gene family with MyD118 and GADD45 and negatively regulates cell growth". Journal of Biological Chemistry.
48. (June 2002). "Proliferating cell nuclear antigen associates with histone deacetylase activity, integrating DNA replication and chromatin modification". Journal of Biological Chemistry.
49. (November 2000). "PCNA interacts with hHus1/hRad9 in response to DNA damage and replication inhibition". Oncogene.
50. (October 2001). "UV-induced binding of ING1 to PCNA regulates the induction of apoptosis". Journal of Cell Science.
51. (October 2001). "A tumor necrosis factor alpha- and interleukin 6-inducible protein that interacts with the small subunit of DNA polymerase delta and proliferating cell nuclear antigen". Proceedings of the National Academy of Sciences of the United States of America.
52. (October 2002). "A proteomics approach to identify proliferating cell nuclear antigen (PCNA)-binding proteins in human cell lysates. Identification of the human CHL12/RFCs2-5 complex as a novel PCNA-binding protein". Journal of Biological Chemistry.
53. (March 2001). "Chromatin-bound PCNA complex formation triggered by DNA damage occurs independent of the ATM gene product in human cells". Nucleic Acids Research.
54. (December 2000). "Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen". Journal of Biological Chemistry.
55. (November 2000). "Functional interaction of proliferating cell nuclear antigen with MSH2-MSH6 and MSH2-MSH3 complexes". Journal of Biological Chemistry.
56. (February 2001). "Human homolog of the MutY repair protein (hMYH) physically interacts with proteins involved in long patch DNA base excision repair". Journal of Biological Chemistry.
57. (October 2005). "Towards a proteome-scale map of the human protein-protein interaction network". Nature.
58. (October 2003). "Human proliferating cell nuclear antigen, poly(ADP-ribose) polymerase-1, and p21waf1/cip1. A dynamic exchange of partners". Journal of Biological Chemistry.
59. (October 1996). "Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA". Cell.
60. (May 2001). "A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome". The EMBO Journal.
61. (July 2002). "Direct interaction of proliferating cell nuclear antigen with the small subunit of DNA polymerase delta". Journal of Biological Chemistry.
62. (March 2003). "Identification of a novel protein, PDIP38, that interacts with the p50 subunit of DNA polymerase delta and proliferating cell nuclear antigen". Journal of Biological Chemistry.
63. (November 2001). "Physical and functional interactions of human DNA polymerase eta with PCNA". Molecular and Cellular Biology.
64. (February 2002). "Stimulation of DNA synthesis activity of human DNA polymerase kappa by PCNA". Molecular and Cellular Biology.
65. (December 2002). "Human DNA polymerase lambda functionally and physically interacts with proliferating cell nuclear antigen in normal and translesion DNA synthesis". Journal of Biological Chemistry.
66. (July 2002). "Over-expression of human DNA polymerase lambda in E. coli and characterization of the recombinant enzyme". Genes to Cells.
67. (September 2002). "A Mammalian bromodomain protein, brd4, interacts with replication factor C and inhibits progression to S phase". Molecular and Cellular Biology.
68. (January 1997). "Replication factor C interacts with the C-terminal side of proliferating cell nuclear antigen". Journal of Biological Chemistry.
69. (April 1999). "The DNA-binding subunit p140 of replication factor C is upregulated in cycling cells and associates with G1 phase cell cycle regulatory proteins". Journal of Molecular Medicine.
70. (January 1993). "The subunits of activator 1 (replication factor C) carry out multiple functions essential for proliferating-cell nuclear antigen-dependent DNA synthesis". Proceedings of the National Academy of Sciences of the United States of America.
71. (August 2008). "Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks". Proceedings of the National Academy of Sciences of the United States of America.
72. (March 2008). "Human HLTF functions as a ubiquitin ligase for proliferating cell nuclear antigen polyubiquitination". Proceedings of the National Academy of Sciences of the United States of America.
73. (February 2008). "hMMS2 serves a redundant role in human PCNA polyubiquitination". BMC Molecular Biology.
74. (February 2003). "Characterisation of the interaction between WRN, the helicase/exonuclease defective in progeroid Werner's syndrome, and an essential replication factor, PCNA". Mechanisms of Ageing and Development.
75. (June 2000). "Characterization of the human and mouse WRN 3'→5' exonuclease". Nucleic Acids Research.
76. (2004). "XRCC1 co-localizes and physically interacts with PCNA". Nucleic Acids Research.
77. (January 1999). "Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen". Cancer Research.
78. (2012). "Nucleotide excision repair is associated with the replisome and its efficiency depends on a direct interaction between XPA and PCNA". PLOS ONE.
79. (August 2012). "Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after replication stress". Molecular Cell.
80. (July 2013). "The helicase FBH1 is tightly regulated by PCNA via CRL4(Cdt2)-mediated proteolysis in human cells". Nucleic Acids Research.
81. (29 May 2015). "Discrimination of cell cycle phases in PCNA-immunolabeled cells". BMC Bioinformatics.
82. (3 September 2014). "A novel cell permeable DNA replication and repair marker.". Nucleus.
83. (April 2014). "PCNA: a silent housekeeper or a potential therapeutic target?". Trends in Pharmacological Sciences.
84. (December 2018). "The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA". Clinical Cancer Research.
85. (July 2023). "Small molecule targeting of transcription-replication conflict for selective chemotherapy". Cell Chemical Biology.